TP53 is one of the most frequent concomitant mutations in NSCLC, and has been associated with poor prognosis of not only patients with EGFR-mutant NSCLC treated with EGFR-TKI but also patients with ALK-rearranged NSCLC treated with crizotinib or chemotherapy [17, 18, 25, 26]. This evidence concerns the gene TP53 and non-small cell lung carcinoma.